Wave Life Sciences is trading 5.1% down at $5.43 after reporting a wider-than-expected second-quarter loss and revenue that missed analyst estimates.
- The company reported a net loss of $69.4 million for the quarter, with revenue dropping to $2.3 million.
- Management highlighted a strong cash runway extending into Q3 2028 and continued progress across its clinical pipeline.